Rutgers Cancer Institute of New Jersey
195 Little Albany Street
New Brunswick, NJ 08903-2681
Dr. Goodin Authors Editorial in the Journal of Clincal Oncology
Susan Goodin, PharmD talks with NJ 101.5's David Matthau about CINJ's ability to offer clinical trials as the state's only NCI-designated comprehensive cancer center.
Professor of Medicine, Division of Medical Oncology, Robert Wood Johnson Medical School
Adjunct Professor, Pharmacy Practice and Administration
Ernest Mario School of Pharmacy, Rutgers University
Susan Goodin received her PharmD degree from the University of Kentucky. She then completed an American Society of Health-System Pharmacy (ASHP)-accredited Pharmacy Practice Residency at the University of Kentucky Medical Center, and an Oncology Pharmacy Residency at the Lucille P. Markey Cancer Center in conjunction with the University of Kentucky Medical Center. Dr. Goodin is an active clinician and researcher. She has expertise in the development and conduct of cancer clinical trials and directs the implementation of translational clinical trials at The Cancer Institute of New Jersey. Her research focus is on the development of novel agents and combinations for the treatment of prostate cancer and natural products for the prevention of cancer.
Dr. Goodin has published more than 60 peer-reviewed articles on the treatment and prevention of cancer demonstrating her leadership in practice and patient care. She served on the Editorial Board of the American Journal of Health-System Pharmacy, was the founding editor-in chief of The Oncology Pharmacist and is currently on the Editorial Board of Clinical Therapeutics. She also serves as a reviewer for a number of pharmacy and cancer journals. Dr. Goodin serves on the Board of Pharmacy Specialties, where she is the past Chair, and previously served on the Oncology Specialty Council. She is a past recipient of the ASHP Section of Clinical Specialists and Scientists Distinguished Service Award, the Cancer Institute of New Jersey Award of Hope for Patient Care, and the Hematology Oncology Pharmacy Association (HOPA) Award of Excellence.
Cooperative Group Chemoprevention Studies
Eastern Cooperative Oncology Group/NCI
Role: Principal Investigator
June 1, 2012 – May 31, 2016
Cancer Center Support Grant
Role: Office of Human Research Services Shared Resource Director
Assistant Director of Clinical Sciences
March 1, 2012 – February 28, 2017
Ha Y-S, Goodin S, DiPaola RS, Kim I. Enzalutamide for castration resistant prostate cancer. Drugs of Today (Barc) 2013;49(1):7-13.
Goodin S, DiPaola RS. Carbozatinib in prostate cancer: The beginning of a precision paradigm? J Clin Oncol 2013;31(4):401-403.
Stein MN, Goodin S, Doyle-Lindrud S, Silverberg J, Kane M, Metzger D, Eddy S, Shih W, DiPaola RS. Transdermal estradiol in castrate and chemotherapy resistant prostate cancer. Med Sci Monit 2012;18(4):CR260-4.
Stein MN, Goodin S, DiPaola RS. Abiraterone in Prostate Cancer: a new angle to an old problem. Clin Cancer Res 2012;18(7):1848-56.
Gounder MK, Lin H, Stein M, Goodin S, Bertino JR, Kong A-H T, DiPaola RS. A validated bioanalytical HPLC method for pharmacokinetic evaluation of 2-deoxyglucose in human plasma. Biomed Chromatogr 2012 May;26(5):650-4.
Lin H, Goodin S, Strair RK, DiPaola RS, Gounder M. Comparison of LC-MS assay and HPLC assay of busulfan in clinical pharmacokinetics. ISRN Analytical Chem 2012, Article ID 198683.
Zheng X, Cui XX, Khor TO, Huang Y, DiPaola RS, Goodin S, Lee MJ, Yang CS, Kong A-N, Conney A. Inhibitory effect of a gamma-tocopherol mixture of tocopherols on the formation and growth of LNCaP prostate tumors in immunodeficient mice. Cancers 2011;3:3762-3772.
Goodin S. Insomnia: What if I were your sister? Pharmacy Today, Health System Edition 2011;17 (November): 2.
Meier K, Griffith N, Chen B, Chuk K, Daouphars M, Doreau C, Patel RA, Schwartz RS, Tames MJ, Terkola R, Badnais B, Wright D, Goodin S. Safe handling of oral chemotherapeutic agents: a European perspective. Eur J Oncol Pharm 2011;5(2): 4-10.
Goodin S. Insomnia: Safeguarding oncology medications. Pharmacy Today, Health System Edition 2011; 17 (September):2.
Meier K, Griffith N, Goodin S. Safe handling of oral chemotherapeutic agents: a European perspective. Eur J Oncol Pharm 2011/2;5:4-10.
Goodin S, Griffith N, Chen B, Chuk K, Daouphars M, Doreau C, Pater RA, Schwartz R, Tames MJ, Terkioa R, Vadnais B, Wright D, Meir K. Safe handling of oral chemotherapeutic agents in clinical practice: recommendations from an international pharmacy panel. J Oncol Practice 2011; 7(1):7-12.
Suh DC, Powers CA, Barone JA, Shin H, Kwon J, Goodin S. Full costs of dispensing and administering fluorouracil chemotherapy for outpatients: a microcosting study. Res Social Adm Pharm 2010 Sep; 6(3):246-256.
Stein M, Dvorzhinski D, Goudner M, Bray K, Eddy S, Goodin S, White E, DiPaola RS. Targeting tumor metabolic fragility with 2-deoxyglucose in patients with castrate resistant prostate cancer and advanced malignancies. Prostate 2010; 70(13):1388-1394.
Toppmeyer DL, Goodin S. Ixabepilone, a new treatment option for metastatic breast cancer. Am J Clin Oncol 2010;33(5);516-521.
Saraiya B, Goodin S. Management of Venous Thromboembolism and the Potential to Impact Overall Survival in Cancer Patients. Pharmacotherapy 2009;29(11):1344-1356.
Wong ST, Goodin S. Overcoming drug resistance in breast cancer. Pharmacotherapy 2009;29(8):954-965.
Goodin S. Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer. Am J Health Sys Pharm 2008;65:2017-2026.
Medina PJ, Goodin S. Lapatinib: A review of the dual inhibitor of epidermal growth factor receptor tyrosine kinase. Clinical Therapeutics 2008; 30 (8):1426-1447.
Goodin S, Shih WJ, Gallo M, Aisner J, DiPaola RS. Effect of Soy Protein on Testosterone Levels. Cancer Epidemiol Biomarkers Prev 2007;16(12):2796.
Georgy A, Neceskas J, Goodin S. Antiemetic care for patients with breast cancer: treatment considerations with a focus on drug interactions and safety. Am J Health Sys Pharm 2007;64:2227-2236.Nishioka JM, Goodin S. Low-Molecular-Weight Heparins in Cancer-Associated Thrombosis: Treatment, Secondary Prevention, and Beyond. J Oncol Pharm Practice 2007;13(2):85-97.
Hait WN, Alli E, Rubin E, Goodin S. Tubulin Targeting Agents. Update on Cancer Therapeutics. (27 Dec 2006 published online) 2007;2 (1) March 1-18.Goodin S, Shen F, Dave N, Shih WJ, Kane MP, Medina P, Lambert GH, Gallo M, DiPaola RS. Clinical and biological activity of soy protein powder supplementation in healthy male volunteers. Cancer Epidemiol Biomarkers Prev 2007: April 16(4):829-33.
Tan AR, Moore DF, Hidalgo M, Doroshow JH, Poplin EA, Goodin S, Mauro D, Rubin EH. Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. Clin Cancer Res 2006; 12(21):6517-6522.Goodin S. Erlotinib: Optimizing Therapy with Predictors of Response? Clin Cancer Res 2006;12(10):2961-2963.
Boehnke-Michaud L, Goodin S. Cancer treatment-induced bone loss, Part 2. Am J Health Sys Pharm 2006;63:534-546.Boehnke-Michaud L, Goodin S. Cancer treatment-induced bone loss, Part 1. Am J Health Sys Pharm 2006;63:419-430.
Blower P, de Wit R, Goodin S, Aapro M. Drug-drug interactions in oncology: why are they important and can they be minimized? Crit Rev in Oncol Hematol 2005;55:117-142.Goodin S, Rao K, Kane M, Capanna T, Engle E, Ciardella M, Todd M, DiPaola, RS. A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer with and without prior chemotherapy. Cancer Chemother Pharmacol 2005;56:199-204.
Lindley C, Goodin S, McCune J, Kane M, Amamoo A, Shord S, Pham T, Yowell S, Laliberte K, Schell M, Bernard S, Socinski M. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone. Am J Clin Oncol 2005;28:270-276.Goodin S, Medina P, Capanna T, Winnie J, Shih J, Abrams S, Doyle-Lindrud S, Rao KV, Todd MB, DiPaola RS. A phase II trial of docetaxel in patients with D0 prostate cancer. J Clin Oncol 2005;23(15)3352-3357.
Rao K, Goodin S, Levitt MJ, Dave’ N, Shih WJ, Lin Y, Capanna T, Doyle-Lindrud S, Todd MB, DiPaola RS. A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate 2005;62(2):115-122.Goodin S, August DA. Commentary on adenoma recurrences after resection of colorectal carcinoma. Am J Oncol Rev 2004:3(9):538-540, 557.
Rabin C, Leventhal H, Goodin S. Conceptualization of disease time-line predicts post-treatment distress in breast cancer patients. Health Psychology 2004;23(4):407-412.Kumar P, Perrotti M, Weiss, R, Todd M, Goodin S, Cummings K, DiPaola R. Phase I trial evaluating the maximally tolerated dose of weekly docetaxel with concurrent 3-D conformal radiation therapy in the treatment of localized unfavorable adenocarcinoma of the prostate. J Clin Oncol 2004;22(10):1909-1915.
Goodin S, Kane M, Rubin EH. Epothilones: Mechanism of action and biological activity. J Clin Oncol 2004;22(10):2015-2025.Goodin S, Shiff SJ. NSAIDs for the chemoprevention of oral cancer: Promise or Pessimism? Clin Cancer Res 2004;10 (5):1561-1564.
Toppmeyer DL, Gounder M, Much J, Musanti R, Vyas V, Medina M, Orlando T, Pennick M, Lin Y, Shi W, Goodin S, Rubin E. A phase I and pharmacologic study of the combination of marimastat and paclitaxel in patients with advanced malignancies. Med Sci Monit 2003;9(8):PI99-104.Thalasila A, Poplin E, Shih J Dvorzhinski D, Capanna T, Doyle-Lindrud S, Beers S, Goodin S, Rubin E, DiPaola RS. A phase I trial of weekly paclitaxel, 13-cis-retinoic acid, and interferon alpha in patients with prostate cancer and other advanced malignancies. Cancer Chemother Pharmacol 2003;52(2):119-124.
Goodin S, Cunningham R. In reply: Evidence for equivalent cardiotoxicity of the 5HT3 receptor antagonists. The Oncologist 2003;8(2): 219-221.
DiPaola RS, Rubin E, Toppmeyer D, Eid J, Butzbach D, Dvorzhinski D, Capanna T, Ciardella M, Shih WJ, Goodin S, Todd MB. Gemcitabine combined with sequential paclitaxel and carboplatin in patients with urothelial cancers and other advanced malignancies. Med Sci Monit 2003;9(2):P5-P11.
Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F, Schran H, Seaman J, Skerjanec A. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002;42(11):1228-1236.Goodin S, Cunningham R. 5-HT3-receptor antagonists for the treatment of nausea and vomiting – a re-appraisal of their side-effect profile. The Oncologist 2002;7(5)424-436.
DiPaola RS, Rinehart J, Nemunitis J, Ebinghaus S, Rubin E, Capanna T, Ciardell M, Doyle-Lindred S, Goodin S, Fontaine M, Adams N, Williams A, Schwartz M, Winchell G, Wickersham K, Deutsch P, Yao S-L. Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. J Clin Oncol 2002;20 (7);1874-1879.
Goodin S, Rao K, DiPaola RS. State of the art treatment of metastatic hormone-refractory prostate cancer. The Oncologist 2002;7 (4):360-370.
DiPaola RS, Chenven ES, Shih WJ, Lin Y, Amenta P, Goodin S, Shumate A, Capanna T, Ciardella M, Cummings K, Aisner J, Todd MB. Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate cancer. Cancer 2001;92(8):2065-2071.
Rao K, Goodin S. Prevention and management of colorectal cancer in women. J Am Pharm Assoc 2001;41:585-595.
Eid JE, Brunner M, Segal L, Cummings KB, Weiss RE, Goodin S, Todd M, Aisner J, DiPaola RS. Effect of P-30 protein and tamoxifen on plasma TGF-beta 1 and IGF-1 in patients with cancer of the prostate. Urol Oncol 2001;6:243-247.
Ahmed F, Vyas V, Cornfield A, Goodin S, Ravikumar TS, Rubin E, Gupta E. In vitro activation of irinotecan to SN-38 by human liver and intestine. Anticancer Research 1999;19:2067-2072.
DiPaola RS, Rafi MM, Vyas V, Toppmeyer D, Rubin E, Pater G, Goodin S, Medina M, Medina P, Zamek R, White E, Gupta E, Hait WN. Phase I clinical and pharmacologic study of 13-cis retinoic acid, alpha interferon, and paclitaxel in patients with prostate cancer and other advanced malignancies. J Clin Oncol 1999;17(7):2213-2218.
Medina P, DiPaola RS, Goodin S. Treatment of hormone-refractory prostate cancer. J Oncol Pharm Practice 1999;5(1):32-48.
Gupta E, Toppmeyer D, Zamek R, Much J, Ibrahim N, Goodin S, Kane M, Aisner J, Li X, Haluska P, Medina M, Cornfield A, Vyas V, Natelson E, Giovanella B, Saleem A, Rubin E. Clinical evaluation of a strategy of sequential topoisomerase targeting in the treatment of advanced malignancy. Cancer Therapeutics 1998;1 (5):292-301.
Goodin S, DiPaola RS. Strategies for using cytoprotective agents to improve outcomes associated with cancer chemotherapy. Disease Management and Clinical Outcomes 1998;1(5):155-160.
Goodin S. Rituxan (RituximabTM). Cancer Therapeutics 1998;1(4):267-270.
DiPaola RS, Zhang H, Lambert G, Mecker R, Licitra E, Rafi MM, Zhu BT, Spaulding H, Goodin S, Toledano MB, Hait WM, Gallo M. Clinical and biological activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med 1998:339(12):785-791.
DiPaola RS, Rodriquez R, Goodin S, Recio A, Orlick M, Mollman J, Bird S, Schuchter L. Amifostine and dose-intense paclitaxel in patients with advanced malignancies. Cancer Therapeutics 1998;1:11-17.
DiPaola RS, Weiss R, Cummings KB, Kong FM, Jirtle RL, Anscher M, Gallo J, Goodin S, Thompson S, Rasheed Z, Aisner J, Todd MB. Effect of 13-cis-retinoic acid and -interferon on transforming growth factor β1 in patients with rising prostate-specific antigen. Clin Can Res 1997;3:1999-2004.
DiPaola RS, Goodin S, Ratzell M, Florczyk M, Karp G, Ravikumar TS. Chemotherapy for metastatic melanoma during pregnancy. Gynecol Oncol 1997 Sep;66(3):526-530.
Goodin S, Gosland MP. Evaluation of 5-HT3-receptor antagonists in emetogenic chemotherapy regimens. Formulary 1996; 31 (11):1071-1080.
Gosland MP, Goodin S, John WJ. A phase I trial of 5-day continuous infusion cisplatin and interferon alpha. Cancer Chemother Pharmacol 1995; 37(1-2):39-46.
Gosland MP, Tsuboi C, Hoffman T, Goodin S, Vore M. 17-estradiol glucuronide: An inducer of cholestasis and a physiological substrate for the multidrug resistance transporter. Cancer Res 1993;53(22):5382-5385.
Tsubaki T, Goodin S, Leader WG, Chandler MH. Estimation of creatinine clearance in patients with gynecologic cancer. Clin Pharm 1993;12(9):685-690.